| Document |
Document Title |
|
WO/2013/164801A1 |
The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceut...
|
|
WO/2013/161816A1 |
The present invention provides a compound represented by general formula (I) [wherein each symbol is as defined in the description], which has an excellent peripheral blood lymphocyte-reducing activity and is useful for the treatment or ...
|
|
WO/2013/157926A1 |
Title: Geranyl geranyl acetone analogs and uses thereof. Abstract The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of a...
|
|
WO/2013/157955A1 |
The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula ...
|
|
WO/2013/157528A1 |
Provided is a medicinal agent comprising a compound represented by general formula (1), a pharmaceutically acceptable salt of the compound or a solvate of the compound or the pharmaceutically acceptable salt. A compound represented by ge...
|
|
WO/2012/084231A9 |
The invention relates to photochromic anellated naphthopyrans having a benzene ring which is adjacent to the pyran acid and is linked to the para substituents via both meta positions, and to use thereof in plastics of all types, in parti...
|
|
WO/2013/146322A1 |
This colored curable composition contains a colored compound containing: (A) at least one type of dye compound selected from a group of compounds represented by general formulas (I-1) and (I-2); and (B) a porphyrin compound represented b...
|
|
WO/2013/144857A1 |
The present application relates to an improved process for the preparation of (S)- equol (1). The present application also relates to novel intermediates of formula (7), (7A), (8) and (9) and their use for the synthesis of (S)-equol.
|
|
WO/2013/141143A1 |
Provided is a novel photochromic compound with favorable durability wherein the color during coloring is an intermediate color (exhibits double peak properties), color intensity is high, and color fading is rapid. For example, a chromene...
|
|
WO/2013/140969A1 |
The present invention is a photoresist composition which contains [A] a polymer that has a structural unit (I) containing an acid-cleavable group and a compound (I) that is represented by formula (1). In formula (1), each of R1, R2, R3 a...
|
|
WO/2013/142236A1 |
Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.
|
|
WO/2013/139487A1 |
The present invention relates to flavone derivatives and to compositions containing one or more of these flavone derivatives. The present invention further relates to fiavone derivatives or compositions for use in the treatment and/or pr...
|
|
WO/2013/135647A1 |
This invention is in the field of experimental medicine. It provides means and methods for preventing or reducing postoperative adhesions. In particular, it provides a compound according to formula (1) for use in preventing or reducing p...
|
|
WO/2013/127361A1 |
A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their ...
|
|
WO/2013/129661A1 |
The present invention provides a chroman derivative represented by general formula (I), which enables the production of an SMTP compound that has a desired structure. In the formula, each of Y1 and Y2 independently represents a hydrogen ...
|
|
WO/2013/130020A1 |
The invention relates to semi-synthetic derivatives of quercetin formula I and pharmaceutically acceptable salts, hydrates and solvates, wherein groups R1 to R5, identical or different, are independently H, benzyl, and at least one group...
|
|
WO/2013/124828A1 |
The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions...
|
|
WO/2013/121209A1 |
A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: (Formula (I)) wherein either Q1, CR6a and optionally R6b together form a cyclic moiety whe...
|
|
WO/2013/121284A1 |
The present invention concerns an iodinated lipophilic compound of formula (I) or (II) : AG-R (I) or AG-X-R (II) wherein - AG represents an unsaturated or saturated (C8-C52) aliphatic hydrocarbon chain found in fatty acids having or not ...
|
|
WO/2013/113331A1 |
The invention relates to a method for an extraction from wood, having the following steps: providing wood particles of at least one first class and wood particles of a second class, stacking a fine layer consisting of the wood particles ...
|
|
WO/2013/115619A2 |
The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof exhibiting antibacterial activity, an extract comprising the compound from a Penicillium sp. strain, a fraction of the extract, an antibacter...
|
|
WO/2013/110796A1 |
The present invention relates to thiazolidinedione derivatives, to the processes for preparing same and to the therapeutic use thereof for preventing or treating cancer, and more specifically breast cancer. These compounds are of formula...
|
|
WO/2013/111850A1 |
The present invention addresses the problem of providing a compound or a pharmacologically acceptable salt thereof, said compound being to be used for promoting osteogenesis, improving bone metabolism, preventing or treating bone fractur...
|
|
WO/2013/111148A1 |
The present invention provides a process for preparation of Luteolin by deprotection of the corresponding ethers using Lewis acid mediated Ionic complexes, and to compositions containing the same.
|
|
WO/2013/109735A1 |
The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated t...
|
|
WO/2013/104263A1 |
Provided is a polyhydroxy benzopyran ketone compound having the structure as represented by formula (I) and pharmaceutically acceptable salt or pro-drug thereof, as well as pharmaceutical composition containing the compound. The compound...
|
|
WO/2013/105037A1 |
The present invention describes the compound of general formula 1 (Formula 1) their salts or esters for the treatment of diseases that are positively influenced by the inhibition of p53-MDM2 or p53-MDMX interaction. In particular for the...
|
|
WO/2013/099982A1 |
A shikuwasa (Okinawa lime) extract, preferably an extract of a fruit or a leaf of shikuwasa with water and/or an organic solvent, a supercritical extract of a fruit or a leaf of shikuwasa or a subcritical extract of a fruit or a leaf of ...
|
|
WO/2013/100003A1 |
A method for purifying an oligomeric proanthocyanidin, comprising an extraction step of extracting a raw material containing multiple types of oligomeric proanthocyanidins having different degrees of polymerization with an extraction sol...
|
|
WO/2013/096223A1 |
Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds a...
|
|
WO/2013/096878A1 |
Embodiments of the present disclosure related to compounds and compositions derived from G. buchananii baker and methods thereof.
|
|
WO/2013/090921A1 |
Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP- 1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidi
n-l-yl]ethoxy}phenyl)-2H-chromen-7-o...
|
|
WO/2013/088455A1 |
Disclosed herein is single step process for the synthesis of 4-aryl substituted chromanes of compound of formula 2 comprising subjecting 3-aryloxy-l-phenylpropan-l-ol of formula 1 to gold (III) chloride-catalyzed intramolecular Friedel-C...
|
|
WO/2013/089197A1 |
[Problem] To provide: a xanthene compound which has characteristics such as high clarity and color developability, while exhibiting excellent fastness such as heat resistance; and a dye composition of the xanthene compound. [Solution] A ...
|
|
WO/2013/090220A1 |
The present invention relates to indeno-fused naphthopyrans, and in particular indeno[2',3':3,4]naphtho[1,2-b]pyrans having certain groups bonded to the 3, 6, 7, 11, and 13 positions thereof. The indeno-fused naphthopyrans of the present...
|
|
WO/2013/086621A1 |
The present document describes a method for extracting anthocyanin derivatives from a plant source. The method comprises the step of separating a homogenized extract of plant source in a polar acidified solvent for obtaining a residual s...
|
|
WO/2013/086248A1 |
The present invention relates to photochromic materials that include one or more indeno-fused naphthopyrans that have particular groups at the 7, 1 1, and 13 positions thereof, and at the position alpha to the oxygen of the pyran ring th...
|
|
WO/2013/083282A1 |
The invention relates to photochromic bis-indenofused naphthopyrans of the general formula (I) and to the use thereof in synthetic materials of all kinds, in particular for ophthalmic purposes. The photochromic compounds according to the...
|
|
WO/2013/083014A1 |
Disclosed is a daidzein derivative as represented by formula I, or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O-N, N-diethyl-aminoace...
|
|
WO/2013/081046A1 |
A compound shown by the general formula (1), and an antitumor agent containing this compound as an active ingredient. (A)n1-(B)n2… (1); where n1 represents any integer of 6-20, n2 represents any integer of 1-20, A is a group shown by t...
|
|
WO/2013/079223A1 |
The invention provides modulators for the orphan nuclear receptor RORϒ and methods for treating RORϒ mediated diseases by administrating these novel RORϒ modulators to a human or a mammal in need thereof. Specifically, the present inv...
|
|
WO/2013/078086A1 |
The present invention relates to photochromic compounds that include at least two photochromic moieties that are linked together by a multivalent linking group. The multivalent linking group can be selected so as to be flexible and/or su...
|
|
WO/2013/068275A1 |
The invention concerns a polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (1): (P—O) x —Q—(Y) w (1) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionall...
|
|
WO/2013/070998A1 |
Methods for inhibiting the growth of ovarian cancer cells or other serosal cancer cells are disclosed. The method involves exposing the cells to a 2-amino-4H-naphtho[1,2-b]pyran-3-carbonitrile of formula. (I). wherein Y is CR1 or N and Z...
|
|
WO/2013/066067A1 |
Disclosed are a phenol monomer, a polymer for forming a resist underlayer film including same, and a composition for a resist underlayer film including same, which are to be used in a semiconductor lithography process. The phenol monomer...
|
|
WO/2013/061999A1 |
Provided is a method for producing an optically active alcohol with high yield by an industrially advantageous process with use of a low-cost asymmetric catalyst, while using a ketone, which may have various structures, as a starting mat...
|
|
WO/2013/058644A1 |
The invention relates to the use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. Said drug has the effect of lowering plasma glucose concentration following administration. Said drug in...
|
|
WO/2013/055647A1 |
Provided are various compounds comprising the formula Also provided are fluorescent dyes comprising the above compound. Additionally, a fluorescence energy transfer system is provided that comprises the above-described fluorescent dye an...
|
|
WO/2013/020184A9 |
Disclosed herein are flavonoid compounds of formula (I) with variables as defined herein, compositions containing these compounds, methods for their synthesis, and uses of these compounds. In particular, there is provided methods of prev...
|
|
WO/2013/052338A1 |
The present invention relates to photochromic materials that include certain indeno-fused naphthopyrans. The indeno-fused naphthopyrans have an amino group (e.g., a piperidino or morpholino group) bonded to the 6-position and hydrogen or...
|
